期刊
APPLIED SCIENCES-BASEL
卷 10, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/app10072632
关键词
BCG; tuberculosis vaccines; TBVI; EDCTP; IAVI; CTVD
类别
资金
- Ministry of Science [RTI2018-097625-B-I00]
- European and Developing Countries Clinical Trials Partnership (EDCTP) [RIA2016V-1637]
In addition to antibiotics, vaccination is considered among the most efficacious methods in the control and the potential eradication of infectious diseases. New safe and effective vaccines against tuberculosis (TB) could be a very important tool and are called to play a significant role in the fight against TB resistant to antimicrobials. Despite the extended use of the current TB vaccine Bacillus Calmette-Guerin (BCG), TB continues to be transmitted actively and continues to be one of the 10 most important causes of death in the world. In the last 20 years, different TB vaccines have entered clinical trials. In this paper, we review the current use of BCG and the diversity of vaccines in clinical trials and their possible indications. New TB vaccines capable of protecting against respiratory forms of the disease caused by sensitive or resistant Mycobacterium tuberculosis strains would be extremely useful tools helping to prevent the emergence of multi-drug resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据